SAGE Therapeutics Inc (NASDAQ:SAGE) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. trimmed its holdings in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 4.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,497 shares of the biopharmaceutical company’s stock after selling 225 shares during the period. Oppenheimer Asset Management Inc.’s holdings in SAGE Therapeutics were worth $631,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of SAGE. Wealthcare Advisory Partners LLC raised its holdings in shares of SAGE Therapeutics by 150.0% during the third quarter. Wealthcare Advisory Partners LLC now owns 250 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 150 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $44,000. Tobam acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $92,000. Tower Research Capital LLC TRC acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $111,000. Finally, Athanor Capital LP acquired a new stake in shares of SAGE Therapeutics during the second quarter worth $201,000.

SAGE Therapeutics stock opened at $146.40 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.00 and a current ratio of 16.00. SAGE Therapeutics Inc has a one year low of $79.88 and a one year high of $193.56. The firm has a market capitalization of $7.46 billion, a P/E ratio of -18.12 and a beta of 2.49. The company has a 50-day simple moving average of $143.81 and a 200-day simple moving average of $164.16.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several equities analysts have recently commented on the stock. ValuEngine upgraded shares of SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BidaskClub lowered shares of SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, November 1st. HC Wainwright assumed coverage on shares of SAGE Therapeutics in a research report on Wednesday, October 30th. They set a “neutral” rating and a $160.00 price target for the company. William Blair restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $187.78.

In other news, Director James M. Frates sold 8,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $160.58, for a total value of $1,284,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by corporate insiders.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: Swap

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Leave a Reply

Your email address will not be published. Required fields are marked *

*